Literature DB >> 11262406

gp130 plays a critical role in pressure overload-induced cardiac hypertrophy.

H Uozumi1, Y Hiroi, Y Zou, E Takimoto, H Toko, P Niu, M Shimoyama, Y Yazaki, R Nagai, I Komuro.   

Abstract

gp130, a common receptor for the interleukin 6 family, plays pivotal roles in growth and survival of cardiac myocytes. In the present study, we examined the role of gp130 in pressure overload-induced cardiac hypertrophy using transgenic (TG) mice, which express a dominant negative mutant of gp130 in the heart under the control of alpha myosin heavy chain promoter. TG mice were apparently healthy and fertile. There were no differences in body weight and heart weight between TG mice and littermate wild type (WT) mice. Pressure overload-induced increases in the heart weight/body weight ratio, ventricular wall thickness, and cross-sectional areas of cardiac myocytes were significantly smaller in TG mice than in WT mice. Northern blot analysis revealed that pressure overload-induced up-regulation of brain natriuretic factor gene and down-regulation of sarcoplasmic reticulum Ca(2+) ATPase 2 gene were attenuated in TG mice. Pressure overload activated ERKs and STAT3 in the heart of WT mice, whereas pressure overload-induced activation of STAT3, but not of ERKs, was suppressed in TG mice. These results suggest that gp130 plays a critical role in pressure overload-induced cardiac hypertrophy possibly through the STAT3 pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11262406     DOI: 10.1074/jbc.M100814200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways.

Authors:  H Yasukawa; M Hoshijima; Y Gu; T Nakamura; S Pradervand; T Hanada; Y Hanakawa; A Yoshimura; J Ross; K R Chien
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 2.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

3.  Deletion of Interleukin-6 Attenuates Pressure Overload-Induced Left Ventricular Hypertrophy and Dysfunction.

Authors:  Lin Zhao; Guangming Cheng; Runming Jin; Muhammad R Afzal; Anweshan Samanta; Yu-Ting Xuan; Magdy Girgis; Harold K Elias; Yanqing Zhu; Arash Davani; Yanjuan Yang; Xing Chen; Sheng Ye; Ou-Li Wang; Lei Chen; Jeryl Hauptman; Robert J Vincent; Buddhadeb Dawn
Journal:  Circ Res       Date:  2016-04-28       Impact factor: 17.367

4.  SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation.

Authors:  Yutaka Takahashi; Nick Carpino; James C Cross; Miguel Torres; Evan Parganas; James N Ihle
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

Review 5.  Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects.

Authors:  P Fischer; D Hilfiker-Kleiner
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

6.  βIV-Spectrin regulates STAT3 targeting to tune cardiac response to pressure overload.

Authors:  Sathya D Unudurthi; Drew Nassal; Amara Greer-Short; Nehal Patel; Taylor Howard; Xianyao Xu; Birce Onal; Tony Satroplus; Deborah Hong; Cemantha Lane; Alyssa Dalic; Sara N Koenig; Adam C Lehnig; Lisa A Baer; Hassan Musa; Kristin I Stanford; Sakima Smith; Peter J Mohler; Thomas J Hund
Journal:  J Clin Invest       Date:  2018-11-12       Impact factor: 14.808

7.  Differential STAT3 signaling in the heart: Impact of concurrent signals and oxidative stress.

Authors:  Carlos Zgheib; Fouad A Zouein; Mazen Kurdi; George W Booz
Journal:  JAKSTAT       Date:  2012-04-01

Review 8.  SOCS3: A novel therapeutic target for cardioprotection.

Authors:  Hideo Yasukawa; Takanobu Nagata; Toyoharu Oba; Tsutomu Imaizumi
Journal:  JAKSTAT       Date:  2012-10-01

Review 9.  Does Transient Receptor Potential Vanilloid Type 1 Alleviate or Aggravate Pathological Myocardial Hypertrophy?

Authors:  Qiqi Yan; Jun Tang; Xin Zhang; Liuyang Wu; Yunyi Xu; Lihong Wang
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

10.  Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo.

Authors:  Barbara Coles; Ceri A Fielding; Stefan Rose-John; Jürgen Scheller; Simon A Jones; Valerie B O'Donnell
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.